Xenetic Biosciences Inc (XBIO)
| Sector • Healthcare Industry • Major Pharmaceutical Preparations |
| Industry • Major Pharmaceutical Preparations |
| Sector • Healthcare |
Xenetic Biosciences Inc announced memorable behavior, all along the third quarter of 2022
XBIO announced third quarter of 2022 operating deficit of $-0.847786 million
Published 2022-11-12T13:40:38+00:00
Goran Soko / CSIMarket.com Contributer
_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg "Dryvax_pd")
In the third quarter of 2022 the company failed to grow bottom-line, following notable Revenue elevation of 18.605 % to $0.41 million, bottom-line remained unaltered at $0.00 per share, year on year. from the preceding quarter from $0.00 per share, Revenue decreased by -0.59 % from $0.42 million.
In the fiscal interval ending September 30 2022 Xenetic Biosciences Inc reported net loss of $-0.804 million, instead of deficit of $-1.351 million in the comparable quarter a year ago.
Xenetic Biosciences Inc is expected to report next financial results on August 10, 2023.